Your session is about to expire
← Back to Search
Parsaclisib for Marginal Zone Lymphoma
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with a certain type of lymphoma who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 88 Patients • NCT02018861Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a lymph node or lymphoid cancer larger than 1.5 cm by 1.0 cm.My spleen marginal zone lymphoma is confirmed by bone marrow test, not by scans.I am willing to have a biopsy or provide a recent biopsy sample.I am experiencing symptoms of graft versus host disease.My cancer has transformed into diffuse large B-cell lymphoma.I have had lymphoma in my brain or spinal cord.I can take care of myself and am up and about more than half of my waking hours.I had a stem cell transplant from a donor within the last 6 months or from myself within the last 3 months.I am 18 years old or older (19 or older if I am in South Korea).I have been treated with specific cancer drugs targeting PI3K.My lymphoma is confirmed to be of the marginal zone type.
- Group 1: Cohort 1- Closed to Further enrollment
- Group 2: Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other medical studies have included Parsaclisib as a treatment?
"Parsaclisib was first researched in 2017 by scholars at Sapienza University. Currently, there are 10 completed studies and 17 ongoing trials involving parsaclisib. Many of these active clinical trials are based in Santa Maria, Arizona."
What is the aim of this experiment?
"The investigators of this study aim to assess the Objective Response Rate (ORR) of participants over the course of 25 months. ORR is Based on Lugano Classification Criteria. Additionally, they will be looking at secondary outcomes like Duration of response and Best percentage change from baseline in target lesion size. Lastly, Progression-free survival will also be monitored."
Could you please expand on the risks associated with Parsaclisib?
"Since there is only data supporting Parsaclisib's safety and no efficacy data, it received a score of 2."
Is this clinical trial also taking place in other countries besides North America?
"This study is being conducted at 33 different medical facilities, some of which include Central Coast Medical Oncology in Santa Maria, UCLA Healthcare Hematology-Oncology in Santa Monica, and St. Joseph Heritage Healthcare in Santa Rosa."
Are any places still available for people who want to join this clinical trial?
"The clinical trial noted on clinicaltrials.gov appears to be inactive, as the last update was over 4 months ago. This specific study is no longer recruiting patients, but there are 1,778 other trials with open recruitment at this time."
Have other similar medical trials been conducted before?
"There are currently 17 live clinical trials for Parsaclisib across 115 cities and 26 countries. The first clinical trial for Parsaclisib was held in 2017. The study, sponsored by Incyte Corporation, involved 161 patients and completed its Phase 2 drug approval stage. Since 2017 years, 10 studies have been completed."
Share this study with friends
Copy Link
Messenger